

Nick Golding

Director



Contact:

T +61 3 8681 4405

M +61 474 206 667

E nick.golding@clarendonlawyers.com.au

Nick is an equity capital markets specialist and regularly acts for issuers, underwriters and investors in public and private market transactions. Nick also assists clients on ASX Listing Rules compliance, securities law advice, corporate governance matters, shareholder meetings, private mergers and acquisitions, shareholder and joint venture arrangements, commercial contracting, debt capital markets, restructures and general commercial and contractual advice.

Prior to joining Clarendon Lawyers as director in July 2016, Nick spent 8 years in the Herbert Smith Freehills capital markets team, where he was appointed senior associate in 2011.

Nick was included in the 2020 Edition of the Best Lawyers in Australia in equity capital markets law and mergers and acquisitions law. He is also a "Recommended" Victorian corporate lawyer in the 2018 Doyle's Guide.

Nick has acted on a broad range of matters across a number of different industries and sectors. He has particular expertise acting for issuers and underwriters on small and mid-market IPOs and secondary capital raisings.

Nick's experience includes advising on the following transactions:

- regular mandates acting as lead manager's counsel on IPOs and all forms of secondary capital raisings for brokers including Canaccord Genuity, Ord Minnett, Wilsons Corporate Finance, Macquarie, Euroz Securities, PAC Partners and Blue Ocean Equities;
- Telix Pharmaceuticals Limited's \$50 million IPO in November 2017 and acquisition of Atlab and capital raising (2018);
- EVZ Limited's two placements in 2018 and renounceable entitlement offer, placement and debt to equity conversion (2017);
- Cynata Therapeutics' placement to Fidelity (2018);
- Adslot Limited's two-tranche placement (2018);
- Lithium Power International's share placement, share purchase plan and option offer (2016) and share placement and option offer (2017), each requiring the issue of a prospectus, and its option underwriting (2017);
- Proserpine Capital's \$25 million recapitalisation of Condor Energy Services (2018);
- NYSE-listed Genpact Limited's acquisition of the assets of NASDAQ-listed Fiserv Inc.'s Australian cheque processing business (2017);
- kikki.K's Series A funding round to TDM Asset Management (2016);
- iflix Limited's US\$50 million Series A round led by Sky (2016) and its US\$30 million convertible note round led by Philippine Long Distance Telephone Company (2015);
- issuer's counsel on the following IPOs:
 - Integral Diagnostics (2015);
 - Mitula Group (2015);
 - SpeedCast International (2014); and
 - Aconex (2014);
- issuer's counsel on the roll-up acquisitions and IPOs undertaken by iCar Asia (2012) and iBuy Group (2013) and all subsequent capital raisings undertaken by them (up to mid 2016);

Nick Golding

Director



- Murray Goulburn's initial public offering of units in the MG Unit Trust;
- Ridgeback Capital Investments' shareholder-approved \$15 million share, warrant and convertible note investment into Prima BioMed;
- the scoping study phase of the Medibank privatisation; and
- the private equity vendors on certain aspects of the IPOs of Asaleo Care and Estia.
- the IPOs of Myer (2009), Royal Wolf (2011) and Alliance Aviation (2011); and
- the issue of SGX-listed convertible notes by CFS Retail Property Trust (2011) and the issue of ASX-listed convertible notes by Healthscope Notes Limited (2010).

Nick holds Law and Arts degrees from the University of Western Australia. He was admitted to practise in 2006.

Contact:

T +61 3 8681 4405

M +61 474 206 667

E nick.golding@clarendonlawyers.com.au